ARS Pharmaceuticals surges on neffy sales beat, China approval
Needle-free epinephrine spray generates $72.2M in first year as European regulator backs pediatric expansion
ARS Pharmaceuticals shares jumped in Monday trading after the company reported stronger-than-expected results for its needle-free epinephrine spray, marking a milestone year for the San Diego-based biotech as it accelerates international expansion.
The company reported fourth-quarter earnings of -$0.42 per share, beating analyst estimates of -$0.49 by 14.3%, while revenue of $28.1 million exceeded projections ranging from $25.6 million to $25.7 million. More significantly, neffy delivered $72.2 million in U.S. net product revenue during its first full commercial year, according to the company's earnings announcement.
The needle-free intranasal epinephrine spray, which offers an alternative to traditional auto-injectors for treating severe allergic reactions, has rapidly gained traction since receiving FDA approval in 2024. ARS Pharmaceuticals now holds $245 million in cash and short-term investments, providing sufficient runway to reach cash-flow break-even as commercial operations scale.
International expansion is accelerating across three major markets. In February, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending approval for the 1mg dose of EURneffy, designed for children weighing between 15 and 30 kilograms. If approved by the European Commission, the authorization would extend across all EU member states, Iceland, Liechtenstein, and Norway, building on the existing 2mg approval for adults and heavier children.
Perhaps most strategically, China's National Medical Products Administration approved neffy in December, making it the first epinephrine product authorized for community use outside hospital settings in the world's most populous nation. The company expects to begin distribution through Chinese partner Pediatrix Therapeutics by spring 2026, with plans to submit an application for the pediatric 1mg dose shortly.
Simultaneously, Australia's Therapeutic Goods Administration granted approval for both 1mg and 2mg doses in December, covering adults and children aged four years and older weighing at least 15 kilograms. The Australian rollout will proceed through partnership with CSL Seqirus.
Analysts remain bullish on ARS Pharmaceuticals' prospects, with a consensus price target of $28.83 representing approximately 218% upside from the current share price of $9.06. Raymond James maintained a "Strong Buy" rating with a $34 price target, while six analysts currently rate the stock a buy, with zero hold or sell ratings, according to MarketBeat data. Individual price targets range from $12 to $39, reflecting varying degrees of confidence in neffy's commercial trajectory.
Institutional investors have embraced the opportunity, with 91.1% of shares held by institutions, while insiders maintain a 16.8% stake. The stock has recovered from its 52-week low of $6.66 but remains well below its peak of $18.90, suggesting significant room for growth if international expansion proceeds according to plan.
The company reported a full-year 2025 net loss of $171.3 million as it invests in commercial infrastructure and regulatory submissions across multiple jurisdictions. However, the combination of strong U.S. adoption, the China breakthrough, and European pediatric positioning has bolstered confidence in the path to profitability.
With the European Commission decision on the 1mg dose expected in the coming months and China launch imminent, ARS Pharmaceuticals enters a critical period that could validate analyst optimism for the needle-free epinephrine platform. The company's ability to execute across geographies will determine whether the current stock price reflects an opportunity or overestimates the challenges of penetrating established allergy treatment markets.